; To ensure the success of the Uterine SPORE program at M. D. Anderson, the overall goal of the Administrative Core is to provide effective management and administration of all activities relating to each project, core, and developmental program in the SPORE. The Administrative Core will actively work to communicate and disseminate information within our internal SPORE investigators as well as facilitate information sharing and collaborations with other SPOREs and external constituencies. The Core will provide a structure to assure integration of diverse scientific disciplines into a unified multidisciplinary approach for achieving excellence in translational endometrial cancer research. Importantly, the Administrative Core will monitor timelines and ensure both basic science and clinical trial aims are met for all SPORE projects. The Core will provide administrative support to the individual SPORE projects, cores, and developmental programs, as well as to the Internal and External Advisory Committees and the Patient Advocates. The Core will assist in preparation of all reports, abstracts, and manuscripts resulting from SPORE activities. The Administrative Core will assure compliance with regulations at all levels and maintain communication among investigators, as well as with other translational researchers, gynecologic cancer SPOREs, the Gynecologic Oncology Group and SPOREs from other disease sites. The Core will convene all meetings, including the Executive Committee, Internal Advisory Committee, External Advisory Committee, and other educational and regulatory activities. The Administrative Core will provide support for data management and for the integration of a centralized data repository accessible by all SPORE investigators. Dr. Karen Lu, Director ofthe Administrative Core and Principal Investigator for the overall SPORE, will direct these activities with the assistance of the Co-Directors of the Administrative Core and Co-Principal Investigators forthe overall SPORE, Drs. Russell Broaddus, Thomas Burke, and George Stancel, as well as the SPORE Program Manager, Jennifer Stanley.
The primary objective of the Uterine SPORE Administrative Core is to provide effective leadership and administrative support for a broad range of SPORE-related activities to ensure optimal progress and performance of all leaders, investigators, projects, cores, and developmental research and career development programs.
|Rupaimoole, Rajesha; Calin, George A; Lopez-Berestein, Gabriel et al. (2016) miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discov 6:235-46|
|Srivastava, Akhil; Babu, Anish; Filant, Justyna et al. (2016) Exploitation of Exosomes as Nanocarriers for Gene-, Chemo-, and Immune-Therapy of Cancer. J Biomed Nanotechnol 12:1159-73|
|Yuan, Ying; Hess, Kenneth R; Hilsenbeck, Susan G et al. (2016) Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. Clin Cancer Res 22:4291-301|
|Haemmerle, Monika; Bottsford-Miller, Justin; Pradeep, Sunila et al. (2016) FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest 126:1885-96|
|Westin, Shannon N; Sun, Charlotte C; Tung, Celestine S et al. (2016) Survivors of gynecologic malignancies: impact of treatment on health and well-being. J Cancer Surviv 10:261-70|
|McCampbell, A S; Mittelstadt, M L; Dere, R et al. (2016) Loss of p27 Associated with Risk for Endometrial Carcinoma Arising in the Setting of Obesity. Curr Mol Med 16:252-65|
|Guo, Beibei; Li, Yisheng; Yuan, Ying (2016) A dose-schedule finding design for phase I-II clinical trials. J R Stat Soc Ser C Appl Stat 65:259-272|
|Liu, Joyce; Westin, Shannon N (2016) Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know. Gynecol Oncol 141:65-71|
|Wang, Chao; Zhu, Xiaoyong; Feng, Weiwei et al. (2016) Verteporfin inhibits YAP function through up-regulating 14-3-3Ïƒ sequestering YAP in the cytoplasm. Am J Cancer Res 6:27-37|
|Chen, Tenghui; Wang, Zixing; Zhou, Wanding et al. (2016) Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types. BMC Genomics 17 Suppl 2:394|
Showing the most recent 10 out of 456 publications